DL-AP5

DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina[1][2][3].

[1]Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44(2):179-185.|[2]Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63(1):16-30.|[3]Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169(1):120-7.|[4]Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67(2):217-23.|[5]Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28. Int J Biol Macromol. 2024 Oct 28:136767.|Biomed Pharmacother. January 2022, 112446.|Brain Behav Immun. 2023 Jun 5;S0889-1591(23)00141-1.|Brain Res. 2019 Dec 15;1725:146487.|Cell Death Discov. 2020 Sep 17;6:87.|CNS Neurosci Ther. 2022 Nov 15.|Environ Sci Technol. 2023 Aug 9.|Exp Brain Res. 2023 Oct 16.|Front Pharmacol. 2022 Jun 9;13:888308.|J Neurochem. 2022 Jul 1.|J Neuroinflammation. 2024 Mar 26;21(1):76.|Neural Plast. 08 Jul 2021.|Neurochem Int. 2023 Jul 24;105587.|Research Square Print. August 24th, 2022.|Sci Rep. 2024 Aug 20;14(1):19337.|Sens Actuators B Chem. 2020, 129190.|Theranostics. 2021 Mar 4;11(10):4616-4636.|Theranostics. 2023 May 11;13(9):2946-2961.